TruSight Oncology 500 Portfolio by Illumina: Comprehensive Insights, Personalized Solutions

In the pursuit of personalized oncology, the TruSight Oncology 500 Portfolio from Illumina stands as a beacon of innovation, delivering a comprehensive suite of genomic solutions. Among the key offerings is the AmpliSeq module, empowering individuals and families with detailed BRCA1/2 mutation analysis for precise cancer risk assessment and personalized treatment strategies.

The AmpliSeq module within the TruSight Oncology 500 Portfolio is more than a test; it’s a transformative tool that tailors oncological treatments and assesses hereditary mutation risks within families. By offering unparalleled insights, it empowers healthcare providers and individuals to make informed decisions, ushering in a new era of personalized healthcare.

Whether you seek diagnostic support for precise treatment or predictive analysis for family-wide risk assessments, AmpliSeq is your ally in the journey towards more informed and personalized healthcare decisions. Illuminate the path to a healthier future with TruSight Oncology 500 Portfolio by Illumina.

Comprehensive BRCA1/2 Analysis:

AmpliSeq goes beyond conventional testing, employing Next-Generation Sequencing (NGS) to provide in-depth analysis of BRCA1/2 germline mutations. This information is pivotal in guiding targeted therapies and informing decisions on surgical interventions for optimal cancer management.

Diagnostic Support:

Conducted directly on patients, AmpliSeq serves as a powerful tool for determining the most effective precision oncology treatment. It unravels the genetic intricacies of individual cases, contributing to tailored and effective therapeutic approaches.

Predictive Analysis for Families:

AmpliSeq extends its impact to family members, conducting predictive analysis to assess the likelihood of inherited mutation risks. This not only aids in proactive healthcare planning but also plays a crucial role in identifying potential risks within family networks.

  • Tissue Samples for Patients
  • Blood Samples for Family Members

These varied examination types, coupled with a versatile range of sample sources, underscore the adaptability and inclusivity of AmpliSeq within the TruSight Oncology 500 Portfolio.

Benefits of TruSight Oncology 500 Portfolio

Enable Comprehensive Genomic Profiling
Bring the Assay into Your Lab
Integrated, Flexible, and Scalable Workflow
Achieve Timely and Reliable Results